Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.

Area of Science:

• Immunology
• Oncology
• Sex Differences in Biology

Background:

• Sex-based differences in cancer incidence are significant but poorly understood.
• CD4+ T cells are crucial for antitumor immunity, coordinating immune responses and priming CD8+ T cells.
• CD40L expression on CD4+ T cells is vital for dendritic cell activation and effective anti-cancer T cell responses.

Purpose of the Study:

• To investigate the impact of biological sex on CD4+ T-cell responses in a mouse model of bladder cancer.
• To elucidate the mechanisms underlying sex-based disparities in anti-tumor immunity.

Main Methods:

• Utilized a mouse model of bladder cancer to compare immune responses between male and female mice.
• Analyzed CD4+ T-cell responses, including CD40L expression and its downstream effects on dendritic cells.
• Investigated the role of androgen receptor signaling in sex-based immune differences.

Main Results:

• Male mice exhibited impaired immune-mediated tumor control compared to female mice.
• Reduced CD40L expression on CD4+ T cells in males was linked to cell-intrinsic androgen receptor signaling.
• This led to decreased dendritic cell licensing and impaired CD8+ T-cell function in the male tumor microenvironment.

Conclusions:

• Biological sex significantly influences CD4+ T-cell responses to cancer, with males showing deficits.
• Androgen receptor signaling in CD4+ T cells impairs the CD40L-CD40 axis, compromising anti-tumor immunity.
• Targeting the CD40L-CD40 axis can rescue impaired T-cell responses and improve tumor control in males.